Close Menu

NEW YORK ─ Luminex on Thursday announced it has received Emergency Use Authorization from the US Food and Drug Administration for an expanded version of its multiplex NxTag Respiratory Pathogen Panel (RPP) that includes a target for SARS-CoV-2.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.